Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE. Alzheimer’s disease. Lancet 2021, 397: 1577–1590.
Article CAS PubMed PubMed Central Google Scholar
Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol 2017, 133: 665–704.
Article CAS PubMed PubMed Central Google Scholar
Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat Rev Neurol 2020, 16: 199–212.
Article CAS PubMed PubMed Central Google Scholar
Zheng H, Sun H, Cai Q, Tai HC. The Enigma of tau protein aggregation: Mechanistic insights and future challenges. Int J Mol Sci 2024, 25: 4969.
Article CAS PubMed PubMed Central Google Scholar
Laurent C, Buée L, Blum D. Tau and neuroinflammation: What impact for Alzheimer’s disease and tauopathies? Biomed J 2018, 41: 21–33.
Article PubMed PubMed Central Google Scholar
Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: A cross-sectional study. Lancet Neurol 2016, 15: 934–943.
Article CAS PubMed PubMed Central Google Scholar
Wang Q, Huang X, Su Y, Yin G, Wang S, Yu B, et al. Activation of Wnt/β-catenin pathway mitigates blood-brain barrier dysfunction in Alzheimer’s disease. Brain 2022, 145: 4474–4488.
Article PubMed PubMed Central Google Scholar
Merlini M, Sozmen EG, Subramanian KS, Nana AL, Seeley WW, Akassoglou K. Three-dimensional imaging of fibrinogen and neurovascular alterations in Alzheimer’s disease. Methods Mol Biol 2023, 2561: 87–101.
Article CAS PubMed PubMed Central Google Scholar
Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005, 70: 247–299.
Article CAS PubMed Google Scholar
van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MMB. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005, 36: 2637–2641.
Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 2008, 62: 1070–1075.
Article CAS PubMed Google Scholar
Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, et al. Fibrinogen gamma-a chain precursor in CSF: A candidate biomarker for Alzheimer’s disease. BMC Neurol 2007, 7: 14.
Article PubMed PubMed Central Google Scholar
Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, et al. Plasma biomarkers of brain atrophy in Alzheimer’s disease. PLoS One 2011, 6: e28527.
Article CAS PubMed PubMed Central Google Scholar
Yang H, Lyutvinskiy Y, Herukka SK, Soininen H, Rutishauser D, Zubarev RA. Prognostic polypeptide blood plasma biomarkers of Alzheimer’s disease progression. J Alzheimers Dis 2014, 40: 659–666.
Article CAS PubMed Google Scholar
Huang S, Wang YJ, Guo J. Biofluid biomarkers of Alzheimer’s disease: Progress, problems, and perspectives. Neurosci Bull 2022, 38: 677–691.
Article PubMed PubMed Central Google Scholar
Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: Mechanisms, imaging and therapeutics. Nat Rev Neurosci 2018, 19: 283–301.
Article CAS PubMed PubMed Central Google Scholar
Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J Exp Med 2017, 214: 3151–3169.
Article CAS PubMed PubMed Central Google Scholar
Blair LJ, Frauen HD, Zhang B, Nordhues BA, Bijan S, Lin YC, et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun 2015, 3: 8.
Article PubMed PubMed Central Google Scholar
Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82: 1271–1288.
Article CAS PubMed PubMed Central Google Scholar
Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood 2007, 109: 1971–1974.
Article CAS PubMed Google Scholar
Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement 2016, 12: 719–732.
LaFerla FM, Oddo S. Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005, 11: 170–176.
Article CAS PubMed Google Scholar
Rawat P, Sehar U, Bisht J, Selman A, Culberson J, Hemachandra Reddy P. Phosphorylated tau in Alzheimer’s disease and other tauopathies. Int J Mol Sci 2022, 23: 12841.
Article CAS PubMed PubMed Central Google Scholar
Hainsworth AH, Minett T, Andoh J, Forster G, Bhide I, Barrick TR, et al. Neuropathology of white matter lesions, blood-brain barrier dysfunction, and dementia. Stroke 2017, 48: 2799–2804.
Article PubMed PubMed Central Google Scholar
Zhou Z, Liang Y, Zhang X, Xu J, Lin J, Zhang R, et al. Fibrinogen and risk of dementia: A systematic review and meta-analysis. Neurosci Biobehav Rev 2020, 112: 353–360.
Article CAS PubMed Google Scholar
Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol Aging 2015, 36: 608–617.
Article CAS PubMed Google Scholar
Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH. Fibrinogen and altered hemostasis in Alzheimer’s disease. J Alzheimers Dis 2012, 32: 599–608.
Article PubMed PubMed Central Google Scholar
Walsh AC. Anticoagulant therapy for Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1996, 8: 361–362.
Article CAS PubMed Google Scholar
Walsh AC, Walsh BH, Melaney C. Senile-presenile dementia: Follow-up data on an effective psychotherapy-anticoagulant regimen. J Am Geriatr Soc 1978, 26: 467–470.
Article CAS PubMed Google Scholar
Barber M, Tait RC, Scott J, Rumley A, Lowe GO, Stott DJ. Dementia in subjects with atrial fibrillation: Hemostatic function and the role of anticoagulation. J Thromb Haemost 2004, 2: 1873–1878.
Comments (0)